A larger study to assess the relation between plasma adiponectin and CIMT in dyslipidemic and nondyslipidemic and obese and nonobese patients with NAFLD and T2DM will help to explore the antiatherogenic role of adiponectin in patients with NAFLD. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.